Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Antiphospholipid Antibodies and Stroke Management – RPTH
Nov 19, 2026, 04:48

Antiphospholipid Antibodies and Stroke Management – RPTH

RPTH Journal shared a post on LinkedIn about a recent article by Macy L.E. Gatti et al,  published in International Society on Thrombosis and Haemostasis adding:

“Cryptogenic stroke and weakly positive antiphospholipid antibodies: what is the right antithrombotic strategy?

Antiphospholipid antibodies (aPLs) are found in a subset of patients with cryptogenic stroke.

For strongly positive aPLs, warfarin is often favoured, but what should we do when the antibodies are only weakly positive?

Evidence is scarce. A new retrospective cohort study in RPTH Journal from the University of Pennsylvania Health System sheds some light.

Key findings from 47 patients with cryptogenic stroke or TIA and persistent aPLs (30 weakly positive, 17 strongly positive):

  • Clinicians recommended warfarin less often (P equals .007) and antiplatelet agents more often (P equals .03) in patients with weakly positive aPLs
  • Recurrent ischaemic stroke incidence: 0.169 events/person-year in the strongly positive group vs 0.045 in the weakly positive group (HR 3.93; 95% CI 1.14–13.55; P = .03)
  • 3-year stroke-free survival: 93% in weakly positive vs 58% in strongly positive patients
  • Bleeding events were rare in both groups

This signal is useful: patients with weakly positive aPLs had a lower incidence of recurrent stroke despite less intensive antithrombotic therapy, while those with strongly positive aPLs remained at high risk. Prospective studies are needed to define the best treatment for each group.

Title: Management and outcomes in patients with cryptogenic stroke and weakly positive antiphospholipid antibodies

Authors: Macy L. E. Gatti, Steven R. Mess, Adam Cuker

Antiphospholipid Antibodies and Stroke Management - RPTH

Stay updated on all scientific advances with Hemostasis Today.